

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/075,715	02/13/2002	Michael Chopp	1059.00073	9739
KOHN & ASSOCIATES Suite 410 30500 Northwestern Highway Farmington Hills, MI 48334			EXAMINER	
			GEMBEH, SHIRLEY V	
			ART UNIT	PAPER NUMBER
	,		1618	
			MAIL DATE	DELIVERY MODE
			06/03/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)	
10/075,715	CHOPP ET AL.	
Examiner	Art Unit	
SHIRLEY V. GEMBEH	1618	

The amendment document filed on <u>19 May 2009</u> is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

item(s) is required.	none document to be compliant, conceden of the following
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMEN  1. Amendments to the specification:  A. Amended paragraph(s) do not include mark  B. New paragraph(s) should not be underlined  C. Other	ings.
2. Abstract:     A. Not presented on a separate sheet. 37 CFR     B. Other	1.72.
"Annotated Sheet" as required by 37 CFR 1  B. The practice of submitting proposed drawing	he top margin as "Replacement Sheet," "New Sheet," or .121(d). g correction has been eliminated. Replacement drawings s, in compliance with 37 CFR 1.84 are required.
C. Each claim has not been provided with the pof each claim cannot be identified. Note: the number by using one of the following status	kt of all pending claims (including withdrawn claims) proper status identifier, and as such, the individual status in status of every claim must be indicated after its claim identifiers: (Original), (Currently amended), (Canceled), j. (Withdrawn) and (Withdrawn-currently amended).
5. Other (e.g., the amendment is unsigned or not sig <u>Claim 18 is new and was not previously presented</u>	
For further explanation of the amendment format required by	37 CFR 1.121, see MPEP § 714.
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:	
<ol> <li>Applicant is given no new time period if the non-complia filed after allowance. If applicant wishes to resubmit the r entire corrected amendment must be resubmitted.</li> </ol>	
(including a submission for a request for continued exami amendment filed within a suspension period under 37 CF	following. a preliminary amendment, a non-final amendment nation (RCE) under 37 CFR 1.114), a supplemental R 1.103(a) or (c), and an amendment filed in response to a , the correction required is only the corrected section of the
Extensions of time are available under 37 CFR 1.136 amendment or an amendment filed in response to a Quantum filed in respon	
filed in response to a Quayle action; or	nt amendment is a non-final amendment or an amendment unendment is a preliminary amendment or supplemental
/Robert C. Hayes/ Primary Examiner, Art Unit 1649	/S. V. G./ Examiner, Art Unit 1618

<sup>--</sup> The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Continuation Sheet (PTOL-324) Application No. 10/075,715

Continuation of 4(e) Other: The claims of 7/14/08 and 5/19/08 are different. Newly amended claims must show underlines and cross-outs or deletions in relation to previously presented claims.

It is also suggested that claim 19 be incorporated into claim 1 to read "...... phosphodiesterase inhibitors [fincreasing numbers of new brain cells, as indicated by], labeling the new brain cells with BrdU, and identifying increased number of new brain cells by double-labeling the brain cells additionally with the neuronal markers NeuN and MAP2, or the astrocytic marker GFAP, where in brain cells positive for both BrdU and said neuronal markers NeuN and MAP2, or said astrocytic marker GFAP, indicate an increase in nevial cells and increase in the pain cells."